
Cellular therapy consultant | Oncologist | Bioinformatician @uclh @uclcancer @TheCrick
Joined July 2014
- Tweets170
- Following531
- Followers364
- Likes317
Pinned Tweet
Many years in the making! Our work on metastasis in non-small cell lung cancer is out now @Nature. Very grateful to the generous patients who have taken part in #TRACERx and our funders who made this work possible.
Excited to share our recent @SwantonLab @NickyMcGranahan & @MariamJHanjani lab work on the genomic evolution of non-small cell lung cancer metastases in #TRACERx, out @Nature
nature.com/articles/s41586-0…
A quick thread [1/13]
Maise Al Bakir retweeted
Thank you @JAMA_current for highlighting the issue of lung cancer in people who have never smoked. Podcast with JAMA deputy editor Dr Kristin Walter discussing the article available online.
Replying to @JAMA_current
Lung cancer among nonsmoking individuals accounts for 15% to 20% of all lung cancer cases.
Benjamin Solomon, PhD, of @PeterMacCC, discusses this and more with JAMA Deputy Editor Kristin Walter, MD, MS.
🎧 Listen now: ja.ma/4nlcsbj
Maise Al Bakir retweeted
More than doubled! 🚀
🚨 #Lungcancer survival has more than doubled.
New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment.
This is what progress looks like. But it must reach everyone who needs it.
🔗 @NEJMEvidence June 2025
evidence.nejm.org/doi/full/1…
#LCSM
Maise Al Bakir retweeted
Excited to share our study Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancer @EmilyGrist1 @marina_parry @MRCCTU @uclcancer @ProstateUK @PCFnews @Prof_Nick_James @LotanLab @Decipher_VCYT @ChrisSweens1 sciencedirect.com/science/ar…
Maise Al Bakir retweeted
@FreddieVonberg does an excellent job of highlighting risk factors for prolonged ICANS in CART patients at the 2025 BNOS conference @BNOSofficial @uclcancer @uclh
Maise Al Bakir retweeted
Great opportunity to work with myself, @drclaireroddie @maeveannoreilly @paulmaciocia and @drmaiseb in our UCLH cellular therapy team go gain experience of delivering standard of care CAR T and trials in solid onc and AID. uclh.nhs.uk/work-with-us/cur…
CAR-T Fellow post available @uclh. Application deadline 04/06/2025. Working with the fabulous @drclaireroddie @maeveannoreilly @paulmaciocia @drmikenorthend
uclh.nhs.uk/work-with-us/cur…
Maise Al Bakir retweeted
thelancet.com/journals/lanha…
Happy to share 15 year follow-up of our study of early rituximab vs watchful waiting for advanced stage, asymptomatic, low tumour burden FL. Substantial delay in TTNT highlights the value of early R for pts seeking to defer/avoid chemo. #lymsm #lymphoma
Maise Al Bakir retweeted
Newly reported updated results of a study from UCLH and UCL highlights the powerful benefits of a targeted immune therapy for a type of slow-growing blood cancer.
Find out more: buff.ly/Pe9KcVA
#Lymphoma
Maise Al Bakir retweeted
CD19 CAR-T is safe and effective for intra-cardiac NHL. Key to this is multidisciplinary care with cardio-oncology colleagues. Nice piece led by Dan Chen, @arjunkg @kathleencheok @maeveannoreilly @uclh @uclcancer onlinelibrary.wiley.com/doi/…
Maise Al Bakir retweeted
A pan-cancer single-cell RNA-seq atlas of intratumoral B cells dlvr.it/TFNVLL
Maise Al Bakir retweeted
Very pleased to see our work with J Richter, D Isenberg and @drclaireroddie published in @BMTjournal
nature.com/articles/s41409-0…
1/CAR-T cell therapy, is making strides in treating autoimmune diseases and may be the future of treating such conditions
Let’s dive in
Maise Al Bakir retweeted
Thrilled to share our discovery of novel long-deletion #signatures—powerful markers for tracking #MMRd #CancerEvolution, even in low-pass (~0.1X) FFPE samples with low tumour content, using our tool #MILO. Check out our preprint for the full story biorxiv.org/content/10.1101/… (1/8)
Maise Al Bakir retweeted
Yet more evidence that somatic copy number alterations define the malignant transition in many carcinomas - this time in CRC from IBD. Love to know the underlying biology!
Inflammatory bowel disease (#IBD) increases bowel cancer risk: 1/3 of patients with low grade dysplasia (LGD) will get cancer. This risk is very high &reason for treatment. But also major conundrum b/c 2/3 patients with LGD won't get cancer. Can we know who is really at risk? 1/3
Maise Al Bakir retweeted
We found that measurement (by lpWGS) of aneuploidy in LGD (burden & specific genetic alterations) very strongly predicts bowel cancer risk: >90% accurate over 5 years. We think the test is good enough (& cheap & easy enough) to be evaluated for clinical use in years ahead. [2/3]
Maise Al Bakir retweeted
Inflammatory bowel disease (#IBD) increases bowel cancer risk: 1/3 of patients with low grade dysplasia (LGD) will get cancer. This risk is very high &reason for treatment. But also major conundrum b/c 2/3 patients with LGD won't get cancer. Can we know who is really at risk? 1/3
Maise Al Bakir retweeted
Preprint is here: medrxiv.org/content/10.1101/…
Many years work by many amazing people (including): @IbrahimAlBakir1 @yosoykit @gcresswell @NadiaNasreddin @salpienowinski @DrAilsaHart @leedham_simon @BowelsOfStMarks @ICR_London [3/3]
Maise Al Bakir retweeted
Thank you to all at @UCLH and @MacmillanCancer for your tireless work to provide cancer patients with the best care and support.
Marking His Majesty’s return to public duties, The King and Queen spent time with patients to hear about their ongoing treatment and support.
Maise Al Bakir retweeted
Today, King Charles III and Queen Camilla met patients and families living with #cancer to hear their hopes and fears as they received care at our cancer centre.
Thank you for taking the time to listen to our patients' experiences.
Read more: buff.ly/44otiOB
Maise Al Bakir retweeted
It was a great honour to welcome Their Majesties to @uclh today. A wonderful opportunity to meet some of our patients and spend time with our fabulous #OneTeam staff
Today, King Charles III and Queen Camilla met patients and families living with #cancer to hear their hopes and fears as they received care at our cancer centre.
Thank you for taking the time to listen to our patients' experiences.
Read more: buff.ly/44otiOB
























